GVK & QS partnership offers trial outcome data

By Nick Taylor

- Last updated on GMT

Related tags Drug development Rheumatoid arthritis Clinical trial

Following a “significant increase in demand” GVK Biosciences has partnered with Quantitative Solutions (QS) to develop and market clinical trial outcome databases, which they believe can improve drug development.

By offering the databases the partners believe they can support quantitative drug development and provide clients with “valuable insights​” into research and marketing programmes.

The databases are designed to assist drug development teams conduct comparative efficacy and safety analysis, link biomarkers to clinical outcomes, predict trial results and develop differentiation strategies.

Sreeni Devidas, vice president of business development at GVK, explained that “the alliance with QS is a major step to create infrastructure that supports the now mandated model of quantitative drug development​”.

By providing this infrastructure Devidas believes the partners can maximise the usefulness of pharmacokinetic/pharmacodynamic modeling and simulation (M&S) and increase its value in the drug development process.

Developing databases

QS already has databases covering five indications, rheumatoid arthritis and psoriasis, chronic HCV, neuropathic pain, osteoporosis and major depression, and GVK will distribute these globally.

By capturing summary level data for the clinical safety and efficacy outcomes from publicly available data sources the partners intend to add to this portfolio with databases covering dyslipidemia, schizophrenia and Alzheimer’s.

The partners will also support the databases by providing customisation and consulting services to clients. By doing so they believe clients will have maximum flexibility and benefits.

QS claims there has been a “significant increase in demand​” for meta-analyses involving publically available data. Japp Mandema, founder and CEO of QS added that its “customers will benefit greatly from the integrated products and services this partnership provides​”.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers